Nectar Lifescience Ltd
Incorporated in 1995, Nectar Lifesciences
Ltd manufactures APIs and Formulations
and is also in the Menthol business[1]
- Market Cap ₹ 918 Cr.
- Current Price ₹ 41.0
- High / Low ₹ 45.7 / 21.2
- Stock P/E 149
- Book Value ₹ 47.7
- Dividend Yield 0.00 %
- ROCE 5.97 %
- ROE 0.46 %
- Face Value ₹ 1.00
Pros
- Stock is trading at 0.86 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -9.56% over past five years.
- Company has a low return on equity of -1.29% over last 3 years.
- Promoters have pledged 100% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,622 | 1,634 | 1,638 | 1,674 | 1,635 | 1,874 | 2,779 | 2,363 | 1,541 | 1,665 | 1,520 | 1,682 | 1,651 | |
1,332 | 1,345 | 1,371 | 1,436 | 1,411 | 1,638 | 2,514 | 2,143 | 1,432 | 1,507 | 1,467 | 1,530 | 1,493 | |
Operating Profit | 290 | 289 | 267 | 239 | 224 | 236 | 264 | 220 | 109 | 159 | 53 | 152 | 157 |
OPM % | 18% | 18% | 16% | 14% | 14% | 13% | 10% | 9% | 7% | 10% | 3% | 9% | 10% |
16 | 12 | 20 | 6 | 23 | 6 | 6 | 4 | -22 | 11 | 43 | 15 | 13 | |
Interest | 115 | 138 | 126 | 123 | 117 | 115 | 148 | 126 | 112 | 79 | 79 | 87 | 90 |
Depreciation | 76 | 84 | 77 | 57 | 62 | 64 | 63 | 61 | 60 | 57 | 59 | 61 | 61 |
Profit before tax | 115 | 78 | 85 | 64 | 67 | 63 | 59 | 37 | -85 | 34 | -42 | 18 | 20 |
Tax % | 25% | 21% | 22% | 15% | 18% | 17% | 19% | 15% | -14% | 26% | -43% | 73% | |
86 | 62 | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -24 | 5 | 6 | |
EPS in Rs | 3.82 | 2.77 | 2.95 | 2.42 | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | 0.28 |
Dividend Payout % | 3% | 4% | 3% | 4% | 2% | 2% | 2% | 4% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | -10% |
3 Years: | 3% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | -22% |
5 Years: | -37% |
3 Years: | 28% |
TTM: | 123% |
Stock Price CAGR | |
---|---|
10 Years: | 1% |
5 Years: | 26% |
3 Years: | 9% |
1 Year: | 47% |
Return on Equity | |
---|---|
10 Years: | 2% |
5 Years: | -1% |
3 Years: | -1% |
Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
Reserves | 845 | 905 | 936 | 932 | 984 | 1,036 | 1,083 | 1,114 | 1,040 | 1,065 | 1,042 | 1,047 |
879 | 858 | 925 | 962 | 878 | 955 | 903 | 779 | 903 | 860 | 754 | 636 | |
527 | 609 | 628 | 640 | 696 | 710 | 696 | 718 | 423 | 443 | 371 | 486 | |
Total Liabilities | 2,274 | 2,394 | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 |
914 | 948 | 934 | 906 | 881 | 852 | 825 | 785 | 772 | 723 | 662 | 643 | |
CWIP | 139 | 122 | 91 | 99 | 102 | 100 | 100 | 115 | 99 | 85 | 78 | 66 |
Investments | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
1,221 | 1,324 | 1,485 | 1,551 | 1,597 | 1,771 | 1,780 | 1,733 | 1,517 | 1,582 | 1,449 | 1,482 | |
Total Assets | 2,274 | 2,394 | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
361 | 255 | 144 | 169 | 199 | 65 | 239 | 285 | 21 | 95 | 134 | 225 | |
-99 | -90 | -60 | -77 | -18 | -29 | -26 | -33 | -29 | 17 | 52 | -17 | |
-282 | -161 | -61 | -89 | -204 | -40 | -201 | -252 | 11 | -119 | -186 | -205 | |
Net Cash Flow | -20 | 4 | 23 | 3 | -23 | -4 | 12 | -0 | 4 | -8 | -0 | 2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 79 | 84 | 99 | 107 | 112 | 119 | 73 | 61 | 89 | 98 | 67 | 82 |
Inventory Days | 216 | 240 | 253 | 260 | 270 | 226 | 151 | 192 | 185 | 197 | 212 | 215 |
Days Payable | 122 | 139 | 146 | 154 | 167 | 142 | 80 | 104 | 108 | 112 | 100 | 127 |
Cash Conversion Cycle | 172 | 185 | 207 | 213 | 215 | 203 | 145 | 150 | 166 | 182 | 179 | 170 |
Working Capital Days | 137 | 152 | 173 | 178 | 186 | 190 | 129 | 149 | 190 | 198 | 204 | 171 |
ROCE % | 13% | 12% | 11% | 10% | 10% | 9% | 10% | 8% | 3% | 5% | -0% | 6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
20 Aug - Copy of newspaper publication as per Section 91, 96 and 108 of the Companies Act, 2013
- Disclosures In Prescribed Format For Details Of Litigation 16 Aug
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Aug - Copies of newspaper publication of financial results ended on June 30, 2024
- Reg. 34 (1) Annual Report. 14 Aug
- Book Closure For Annual General Meeting ('AGM') To Be Held On 21.09.2024 / E-Voting 14 Aug
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
NLL is a research-driven manufacturer of Active Pharmaceutical Ingredients, intermediates, and finished dosage forms, specializing in anti-infectives like Cephalosporins. It also serves as a CMO for global pharma innovators.